ALRN - Aileron announces pricing of underwritten registered direct offering priced at-the-market under Nasdaq rules of up to about $40M
2024-05-01 09:14:04 ET
More on Aileron Therapeutics
- Aileron Therapeutics announces positive data from its early stage pulmonary fibrosis treatment trial
- Seeking Alpha’s Quant Rating on Aileron Therapeutics
- Historical earnings data for Aileron Therapeutics
- Financial information for Aileron Therapeutics